NCT00859755View on ClinicalTrials.gov

A Safety Study of ARRY-403 in Patients With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL

Enrollment

41

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

July 31, 2009

Conditions

Type 2 Diabetes

Interventions

DRUG

ARRY-403, glucokinase activator; oral

single dose, escalating

DRUG

Placebo; oral

matching placebo

Trial Locations (1)

91911

Profil Institute for Clinical Research, Inc., Chula Vista

Sponsors

Lead Sponsor

Array BioPharma

All Listed Sponsors

lead

Array BioPharma

INDUSTRY

NCT00859755 - A Safety Study of ARRY-403 in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter